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Abstract Lentiviral-mediated gene transfer in vivo or in
cultured mammalian neurons can be used to address a wide
variety of biological questions, to design animals models
for specific neurodegenerative pathologies, or to test
potential therapeutic approaches in a variety of brain dis-
orders. Lentiviruses can infect non-dividing cells, thereby
allowing stable gene transfer in post-mitotic cells such as
mature neurons. An important contribution has been the
use of inducible vectors: the same animal can thus be used
repeatedly in the doxycycline-on or -off state, providing a
powerful mean for assessing the function of a gene can-
didate in a disorder within a specific neuronal circuit.
Furthermore, lentivirus vectors provide a unique tool to
integrate siRNA expression constructs with the aim to
locally knockdown expression of a specific gene, enabling
to assess the function of a gene in a very specific neuronal
pathway. Lentiviral vector-mediated delivery of short
hairpin RNA results in persistent knockdown of gene
expression in the brain. Therefore, the use of lentiviruses
for stable expression of siRNA in brain is a powerful aid to
probe gene functions in vivo and for gene therapy of dis-
eases of the central nervous system. In this chapter I review
the applications of lentivirus-mediated gene transfer in the
investigation of specific gene candidates involved in major
brain disorders and neurodegenerative processes. Major
applications have been in polyglutamine disorders, such as
synucleinopathies and Parkinson’s disease, or in investi-
gating gene function in Huntington’s disease, dystonia, or
muscular dystrophy. Recently, lentivirus gene transfer has
been an invaluable tool for evaluation of gene function in
behavioral disorders such as drug addiction and attention-
deficit hyperactivity disorder or in learning and cognition.
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Introduction
Lentiviral vectors are increasingly used for gene delivery to
neurons and in experimental models of neurodegeneration.
Tackling neurodegenerative diseases represents a formi-
dable challenge for our aging society [1, 2]. Local delivery
of therapeutic molecules represents one of the limiting
factors for the treatment of neurodegenerative disorders.
Gene transfer methods for efficient co-expression of
exogenous proteins in neurons are crucial tools toward the
understanding of the molecular basis of the central nervous
system. In vivo gene transfer using lentiviral vectors con-
stitutes a powerful tool in this area [3]. Major advantages
of lentiviral vectors are their ability to transduce non-
dividing cells including differentiated neurons and to
confer long-term expression of transgenes [4, 5].
In recent years, the breakthrough discovery that double-
stranded RNA of 21 nucleotides in length (referred to as
short or small interfering RNA; siRNA) triggers sequence-
specific gene silencing in mammalian cells led to the
development of a powerful new approach to study gene
function [6–8]. This evolutionarily conserved mechanism is
carried out by an endogenous pathway that centers on the use
of endogenously encoded small RNAs, and can be hijacked
to knockdown the expression of any target protein by
introducing a specific siRNA into a cell [9]. Therefore, the
ability to manipulate the RNA-induced interference (RNAi)
in mammalian cells provided a very powerful tool to
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influence gene expression. Stable knockdown can be
obtained by constitutive expression of the siRNA from the
host chromosome, but neurons represent a cell type that
display resistance to transduction by siRNAs, when
attempting to silence expression of endogenous genes in
these postmitotic cells. Thus for in vivo applications, RNAi
has been hampered until recently by inefficient delivery
methods and by the transient nature of the gene suppression.
However, lentivirus-mediated expression of short hairpin
(sh)RNA was shown to be long-term and mediate stable
RNAi in a dose-dependent manner [10], therefore, providing
a convenient way to integrate RNAi expression constructs.
Besides their ability to infect non-dividing cells, thereby
allowing knockdown in mature neurons, lentiviruses also
improve the efficiency of gene delivery to different cell
types, thus improving the potential usefulness of RNAi as
therapy [10–14]. A number of lentiviral vectors have been
developed for performing sh-directed RNAi in mice [13, 15–
18]. Some vectors encode green fluorescent protein (GFP) as
a marker for infectivity and to track the RNAi knockdown
cells in real time. Other vectors contain antibiotic selection
markers, such as puromycin, which are useful when the cell
selection is imposed. In addition, there are conditional ver-
sions of lentiviral RNAi vectors available, where the user
may opt to ‘‘turn on’’ or ‘‘turn off’’ RNAi during the course
of experimentation [4, 15, 18]. Drug-inducible systems
allowing the control of transgene expression and knockdown
in mammalian cells are invaluable tools for genetic research,
and could also play important roles in translational research
or gene therapy [19]. A lentivector-based, conditional gene
expression system for drug-controllable expression of
transgenes and shRNAs has been established that is highly
robust and versatile, governing tightly controlled expression
of transgenes and endogenous cellular genes in various
primary and established cell lines in vitro, as well as in vivo
in the central nervous system [19]. The Woodchuck hepatitis
virus (WHV) posttranscriptional regulatory element
(WPRE) facilitates nucleocytoplasmic transport of RNA
mediated by several alternative pathways that may be
cooperative and this element has been included in many
different genetherapy vectors including lentivirus, AAV,
adenovirus etc., to stimulate heterologous cDNAs expres-
sion. More recently, insertion of two copies of a human
synapsin promoter/WPRE cassette in a single lentiviral
vector was shown to direct robust co-expression of cDNAs
in cultured neurons, while excluding expression in the sur-
rounding glial cells [5]. In addition, insertion of the tetra-
cycline-inducible system (Tet-off) controlled by the
synapsin promoter results in tightly regulated expression of
EGFP when used as a transgene in cultured neurons This tool
provides neuron-specific and regulated expression mediated
by single lentiviral vectors and will prove valuable tools for
the study of neuronal function [5].
A major breakthrough in our understanding of specific
gene function in many brain disorders has been made
possible by either overexpressing or silencing gene
expression in very specific neuronal pathways. For this
purpose the use of replication uncompetent viruses, pre-
venting the vector to spread away from the injection area,
has been a major advance. Lentiviruses have the additional
advantage that large gene can be inserted and permanently
incorporated into the host cell. Furthermore, the use of
neuron-specific promoters enables cell-specific gene
transfer in a complex system such as the brain. In this
review I will discuss the applications of lentivirus-medi-
ated gene transfer in the investigation of a large variety of
brain disorders, with particular emphasis of the use of
lentiviruses for local gene knockdown.
Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune condition in
which the immune system attacks the central nervous
system, leading to demyelination [20, 21]. Disease onset
usually occurs in young adults [22] with a prevalence that
ranges between 2 and 150 per 100,000 [23]. Multiple
sclerosis affects the white matter of the brain and spinal
cord, destroying the myelin sheath and producing lesions
(scleroses or plaques) in the white matter [22]. Although
much is known about the mechanisms involved in the
disease process, the cause remains unknown. Theories
include genetics or infections [24]. It is not considered a
hereditary disease; however, specific genes have been
linked with multiple sclerosis [25] and genetics may play a
role in determining a person’s susceptibility to multiple
sclerosis.
Differences in the human major histocompatibility
complex increase the probability of suffering multiple
sclerosis [26]. Besides, mutations in the IL-2RA and the
IL-7RA subunits of the receptor for interleukin 2 and
interleukin 7, respectively, are also associated with the
disorder [27, 28]. The histocompatibility complex is
involved in antigen presentation, while mutations in the
IL-2 and IL-7 genes were already known to be associated
with diabetes and other autoimmune conditions, supporting
the notion that multiple sclerosis is an autoimmune disease
[26, 29, 30]. Other studies have linked genes in chromo-
some 5 with the disease [31]. Richardson et al. [32] have
used intrabody-mediated knockout of the high-affinity IL-2
receptor using a bicistronic lentivirus vector, but this has
not yet been evaluated for the disease.
Furthermore, several studies demonstrate that lesions
from patients contain activated transcription factors like
NF-jB, STAT1, STAT3, and STAT6 [33–35], which can
lead to enhanced signaling of inflammatory stimuli. Thus,
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regulation of inflammatory signaling may be altered in MS,
and may be responsible for inflammatory demyelination.
SHP-1 is a protein tyrosine phosphatase with two SH2
domains, which acts as a crucial negative regulator of
cytokine signaling, inflammatory gene expression, and
demyelination in central nervous system via STAT1,
STAT3, and STAT6 [36–39]. Mice genetically lacking in
SHP-1 (motheaten mice) display myelin deficiency, which
may be mediated by increased inflammatory mediators in
the CNS [40, 41]. Christophil et al. [42] established a role
for SHP-1 in MS. The levels of SHP-1 protein and mRNA
in PBMCs of patients were significantly lower compared
to normal subjects. Moreover, promoter II transcripts,
expressed from one of two known promoters, were selec-
tively deficient in patients. As expected, patients had sig-
nificantly higher levels of pSTAT6. Furthermore, siRNA to
SHP-1 effectively increased the levels of phosphorylated
pSTAT6 in PBMCs of controls to levels equal to patients.
Christophil et al. [42] also designed a lentiviral vector
expressing SHP-1 [43]. The vector carried the human SHP-
1 coding sequence, allowing the bicistronic expression of
green fluorescent protein (GFP) and SHP-1 in the trans-
duced cells. Transduction of PBMCs with this lentivirus
lowered pSTAT6 levels. Multiple STAT6-responsive
inflammatory genes were increased in PBMCs of patients
relative to PBMCs of normal subjects. Thus, lentiviruses
may be very efficient tools to assess the mechanisms of
inflammatory demyelination.
Dystonia
Dystonia is a neurological movement disorder in which
sustained muscle contractions cause twisting and repetitive
movements or abnormal postures [44]. The disorder may
be inherited or caused by other factors such as birth-related
or other physical trauma, infection, poisoning (e.g., lead
poisoning), or reaction to drugs. Primary dystonia is sus-
pected to be caused by pathology of the central nervous
system, likely originating in those parts of the brain con-
cerned with motor function, such as the basal ganglia, and
the GABA (c-aminobutyric acid) producing Purkinje neu-
rons. Early onset generalized dystonia is a dominantly
inherited disorder caused by neuronal dysfunction without
an apparent loss of neurons. Most cases of the dominantly
inherited movement disorder, early onset torsion dystonia
(DYT1) are caused by a mutant form of torsinA. The same
single mutation (GAG deletion) causes most cases, and
results in loss of a Glutamine (Glu) in the carboxy terminal
region of torsinA (D302/303) [45]. Relatively little is
understood about the normal function of torsinA or the
physiological effects of the codon deletion associated with
most cases of disease. TorsinA is an ATPase associated
with diverse cellular activities (AAA) protein [46]. It is
apparently involved in membrane structure/movement and
processing of proteins through the secretory pathway and is
located predominantly in the lumen of the endoplasmic
reticulum (ER) [47, 48]. The mutant form of torsinA
[torsinA(DE)] accumulates in the nuclear envelope (NE),
leading to the formation of NE-derived membranous
inclusions known as spheroid bodies that accumulate in the
cytoplasm [49–51]. Overexpression of wild-type torsinA in
cultured cells results in a reticular distribution of immu-
noreactive protein that co-localizes with endoplasmic
reticulum resident chaperones, while the dystonia-related
mutant form accumulates within concentric membrane
whorls and nuclear-associated membrane stacks [52].
Recent studies suggest that the mutant form of torsinA
carrying the disease-linked mutation, torsinA(DE), acts
through a dominant negative effect by recruiting wild-type
torsinA into oligomeric structures in the nuclear enve-
lope [53]. Therefore, suppressing torsinA(DE) expression
through RNAi could restore the normal function of
torsinA(wt), representing a potentially effective therapy
regardless of the biological role of torsinA [54]. Gonzalez-
Allegre et al. [55] generated shRNAs that mediate allele-
specific suppression of torsinA(DE) and rescue cells from
its dominant negative effect, restoring the normal distri-
bution of torsinA(wt). In addition, delivery of this shRNA
by a recombinant feline immunodeficiency virus effec-
tively silenced torsinA(DE) in a neural model of the dis-
ease. They established the feasibility of viral-mediated
RNAi approach by demonstrating significant suppression
of endogenous torsinA in mammalian neurons. Silencing of
torsinA was achieved without triggering an interferon
response. These results support the potential use of viral-
mediated RNAi as a therapy for DYT1 dystonia and
establish the basis for preclinical testing in animal models
of the disease. Further, to model the neuronal involvement,
adult rat primary sensory dorsal root ganglion neurons in
culture were infected with lentivirus vectors expressing
human wild-type or mutant torsinA [56]. Expression of the
mutant protein resulted in formation of torsinA-positive
perinuclear inclusions. When the cells were co-infected
with lentivirus vectors expressing the mutant torsinA
message and a shRNA selectively targeting this message,
inclusion formation was blocked. Vector-delivered siRNAs
have the potential to decrease the adverse effects of this
mutant protein in neurons without affecting wild-type
protein.
A reduced rate of secretion is observed in primary
fibroblasts from DYT1 patients expressing endogenous
levels of torsinA and torsinA(DE) when compared with
control fibroblasts expressing only torsinA [47]. siRNA
oligonucleotides have been used to downregulate the levels
of torsinA or torsinA(DE) mRNA and protein by over 65%
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following transfection. Transfection of siRNA for torsinA
mRNA in control fibroblasts expressing Gaussia luciferase
reduced levels of luciferase secretion compared with the
same cells non-transfected or transfected with a non-spe-
cific siRNA. Transfection of siRNA selectively inhibiting
torsinA(DE) mRNA in DYT fibroblasts increased lucifer-
ase secretion when compared with cells non-transfected or
transfected with a non-specific siRNA. Further, transduc-
tion of DYT1 cells with a lentivirus vector expressing
torsinA, but not torsinB, also increased secretion [47],
consistent with a role for torsinA as an ER chaperone
affecting processing of proteins through the secretory
pathway, and indicating that torsinA(DE) acts to inhibit this
torsinA activity. The ability of allele-specific siRNA for
torsinA(DE) to normalize secretory function in DYT1
patient cells supports its potential role as a therapeutic
agent in early onset torsion dystonia.
Poly(Q)-Disorders
There are at least nine human neurodegenerative disorders
that are caused by polyglutamine extension, i.e., by expan-
sion of the CAG trinucleotide repeat. RNAi has recently
been performed on several prevalent polyglutamine dis-
eases, e.g., spinobulbar muscular atrophy, Machado-Joseph
disease, a-synucleinopathies, Huntington’s disease, and
spinocerebellar ataxia.
Spinobulbar muscular atrophy is an X-linked motor-
neuron disease, related to CAG trinucleotide expansion in
the first exon of the androgen receptor. It occurs at adult-
hood, and results in the loss of motorneurons in the lower
spinal cord and the brain stem. Unaffected individuals have
between 11 and 35 poly(Q) repeats as opposed to 38 and 62
repeats in patients [57, 58]. This poly(Q) expansion results
in intranuclear aggregates formation in tissues where the
androgen receptor gene is normally expressed. Drosophila
S2 cells were engineered to express a portion of human
androgen receptor gene with CAG tracts of 26, 43, or 106
repeats tagged by green fluorescent protein (GFP) [59].
Cells carrying the CAG repeats of 43 and 106 developed
GFP aggregates and aggresomes with 106 aggregates being
formed much faster than 43 CAG repeats. Using RNAi
directed against the androgen receptor mRNA, Caplen
et al. [59] showed loss of aggregates by 80% in co-trans-
fected S2 cells.
Similarly, spinocerebellar ataxia type 1 is another
poly(Q) expansion disease, related to CAG repeats of
ataxin-1 and characterized by slowly progressive inco-
ordination of gait, and often associated with poor coor-
dination of hands, speech, and eye movements,
frequently resulting in cerebellar atrophy. Xia et al. [60]
have also successfully suppressed these symptoms by
RNAi in a mouse model of this disease [60]. These
studies show that RNAi interference could have consid-
erable therapeutic potential in poly(Q) neurodegenerative
disorders.
Machado-Joseph disease (MJD) is a related ataxia and a
fatal, dominant neurodegenerative disorder. MJD results
from polyglutamine repeat expansion in the MJD-1 gene,
conferring a toxic gain of function to the ataxin-3 protein.
Overexpressing ataxin-3 in the rat brain using lentiviral
vectors enabled to study the disorder in defined brain
regions [61]. No neuropathological changes were observed
upon wild-type ataxin-3 overexpression. Mutant ataxin-3
expression in striatum and cortex resulted in accumulation
of misfolded ataxin-3, and within striatum, loss of neuronal
markers. Striatal pathology was confirmed by observation
of ataxin-3 aggregates in MJD transgenic mice and sub-
stantial reduction of the dopamine and cAMP regulated
phosphoprotein (DARPP-32) immunoreactivity and, in
human striata, by ataxin-3 inclusions, immunoreactive for
ubiquitin and a-synuclein [61]. This interesting study
demonstrates the use of LV encoding mutant ataxin-3 to
produce a model of MJD.
Synucleinopathies are caused by aggregates of a-syn-
uclein, due to polyglutamine extension of the mutated
protein. The synuclein family includes three proteins,
a-synuclein, b-synuclein, and c-synuclein, sharing a com-
mon, highly conserved motif with similarity to the class-A2
lipid-binding domains of apolipoproteins. Their function is
poorly known so far, but a-synuclein is mutated in several
families with autosomal dominant Parkinson’s disease
[62]. a-Synuclein is primarily found in neural tissue, where
it is seen mainly in presynaptic terminals. It is predomi-
nantly expressed in the neocortex, hippocampus, substantia
nigra, thalamus, and cerebellum. It is predominantly a
neuronal protein, but can also be found in glial cells [63].
a-Synuclein overexpression and its toxic accumulation in
neurons or glia are known to play key roles in the patho-
genesis of Parkinson’s disease and other related neurode-
generative synucleinopathies. It can aggregate to form
insoluble fibrils in these pathological conditions charac-
terized by ‘‘Lewy bodies,’’ such as Parkinson’s disease,
dementia with Lewy bodies, and multiple system atrophy.
In addition, an a-synuclein fragment, known as the non-
Abeta component (NAC), is found in amyloid plaques in
Alzheimer’s disease.
In rare cases of familial forms of Parkinson’s disease
there is a mutation in the gene coding for a-synuclein.
Three point mutations have been identified thus far: A30P,
E46K, and A53T, In addition, duplication and triplication
of the gene appear to be the cause of Parkinson’s disease
in other lineages. Moreover, genetic variability of the
a-synuclein gene promoter is associated with idiopathic
Parkinson’s disease.
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To develop an animal model of PD, lentiviral vectors
expressing different human or rat forms of a-synuclein
were injected into the substantia nigra of rats [64]. A
selective loss of nigral dopaminergic neurons associated
with a dopaminergic denervation of the striatum was
observed in animals expressing either wild-type or mutant
forms of human a-synuclein. This neuronal degeneration
correlates with the appearance of abundant a-synuclein-
positive inclusions and extensive neuritic pathology and
recapitulates the essential neuropathological features of
PD. The authors conclude that lentiviral-mediated genetic
models may contribute to elucidate the mechanism of
a-synuclein-induced cell death, and allow the screening of
candidate therapeutic molecules [64].
Silencing of the human a-synuclein gene by vector-
based RNAi is a promising therapeutic approach for syn-
ucleinopathies. Fountaine and Wade-Martins [65] achieved
80% protein knockdown using siRNA targeted to endog-
enous a-synuclein and showed that a-synuclein suppression
in vitro decreases dopamine transport and alters cellular
dopamine homeostasis [65]. Sapru et al. reported a 21-
nucleotide sequence in the coding region of human
a-synuclein that constitutes an effective target for robust
silencing by RNAi [66]. Using a dual cassette lentivirus
that co-expresses an a-synuclein-targeting shRNA and
EGFP (as a marker gene), effective silencing of endoge-
nous human a-synuclein in vitro in the human dopami-
nergic cell line SH-SY5Y could be demonstrated and also
in vivo silencing of experimentally expressed human
a-synuclein in rat brain could be achieved successfully
[66]. This may provide the tools for developing effective
gene silencing therapeutics for synucleinopathies, includ-
ing Parkinson’s disease.
a-Synuclein inhibits tyrosine hydroxylase (TH), the rate
limiting enzyme in catecholamine synthesis, which is fre-
quently used as a marker of dopaminergic neuronal loss in
animal models of Parkinson’s disease (PD). TH is activated
by the phosphorylation of key seryl residues in the TH
regulatory-domain. a-Synuclein reduces TH phosphoryla-
tion, which then reduces dopamine synthesis [67, 68].
Using wt human a-synuclein lentivirus, Alerte et al. [69]
transduced dopaminergic neurons in the olfactory bulb of
a-synuclein knockout mice and observed that cells bearing
aggregated a-synuclein, had significantly reduced total
anti-TH immunoreactivity, but high phosphoserine-TH
labeling, which suggests that aggregated a-synuclein is no
longer able to inhibit TH [69].
Huntington’s disease is an autosomal dominant heredi-
tary brain disorder that is progressive and fatal, caused by
expansion of a CAG trinucleotide repeat in exon-1 of the
Huntingtin gene [70]. The precise function of huntingtin is
unknown, but in mice, complete deletion of the huntingtin
gene is lethal. Mutations in this gene result in involuntary
movement (chorea), cognitive impairment and psychiatric
problems such as depression and anxiety [71, 72]. This
expansion elongates the N-terminal poly(Q) stretch of the
protein, resulting in aggregation and the formation of
neuronal intranuclear inclusions that causes an increase in
the rate of neuronal cell death in select areas of the brain,
affecting neurological functions [73, 74]. As Huntington’s
disease is a monogenetic disorder conclusively linked to a
single gene, researchers investigated using gene knock-
down and lentiviral-mediated gene transfer of mutated
huntingtin as a potential treatment [75, 76]. siRNA therapy
achieved a 60% reduction in expression of the mutated
protein in a mouse model and progression of the disease
was stalled [77]. However, using RNA interference to treat
Huntington’s disease could have unexpected effects unless
knockdown of the unmutated huntingtin protein can be
avoided, since full deletion of the normal protein is lethal.
Also off-target effects of siRNA must be avoided [78].
A lentiviral vector expressing a mutant huntingtin pro-
tein (htt171-82Q) was used to generate a chronic model of
Huntington’s disease (HD) in rat primary striatal cultures
[79]. Primary striatal neurons expressing N-terminal frag-
ments of mutant huntingtin in vitro (via lentiviral gene
delivery) faithfully reproduce the gene expression changes
seen in human patients and may serve as models of the
disease [79–81]. Expression of a wild-type fragment of
huntingtin (htt171-18Q) caused only a small number of
RNA changes. The disease-related signal in huntingtin171-
82Q versus huntingtin171-18Q comparisons results in the
differential detection of 20% of all mRNA probe sets [81].
Transcriptomic effects of mutated huntingtin171 are time-
and polyglutamine-length dependent, and occur in parallel
with other manifestations of polyglutamine toxicity over
4–8 weeks. Specific changes in lentivirus-mediated hun-
tingtin171-82Q-expressing striatal cells accurately reca-
pitulated those observed in human patients and included
decreases in specific mRNAs (proenkephalin, regulator of
G-protein signaling-4, dopamine D1 and D2 receptors,
cannabinoid CB1 receptor, and DARPP-32). This lentivi-
ral-transfer study showed that induced dysregulation of the
striatal transcriptome might be attributed to intrinsic effects
of mutant huntingtin [81].
A new strategy based on lentiviral-mediated delivery of
mutant huntingtin (htt) was used to create a genetic model
of Huntington’s disease (HD) in rats and to assess the
relative contribution of polyglutamine (CAG) repeat size.
Lentiviral vectors coding for the first 171, 853, and 1520
amino acids of wild-type (19 CAG) or mutant htt (44, 66,
and 82 CAG) driven by either the phosphoglycerate kinase
1 (PGK) or the cytomegalovirus (CMV) promoters were
injected in rat striatum [82]. Lentiviral-mediated overex-
pression of mutated huntingtin expressing 82 polyglu-
tamine residues protein led to proteolytic release of
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N-terminal huntingtin fragments, nuclear aggregation, and
a striatal dysfunction and accelerate the pathological pro-
cess, as revealed by decrease of DARPP-32 staining but
absence of the neuron-specific nuclear protein NeuN down-
regulation [83]. Heat-shock proteins, which refold dena-
tured proteins, also mitigate Huntington’s disease mice
models; as a matter of fact, based on lentiviral-mediated
overexpression of a mutated huntingtin fragment, Perrin
et al. [84] showed that heat-shock proteins 104 and 27
rescue striatal dysfunction in primary striatal neuronal
cultures and in vivo, in rat models, both chaperones
significantly reduced mutated huntingtin-related loss of
DARPP-32 expression [84]. Furthermore, the trophic fac-
tors CNTF (Ciliary Neurotrophic Factor) and BDNF
(Brain-Derived Neurotrophic Factor) are neuroprotective in
acute Huntiongton’s models and prevent striatal degener-
ation in a chronic model. Results demonstrated that both
agents were neuroprotective without modifying inclusion
formation [79]. Lentiviral vectors expressing the human
CNTF were injected in the striatum of wild-type and
transgenic mice expressing full-length huntingtin with 72
CAG repeats; behavioral analysis showed increased loco-
motor activity in 5- to 6-month-old treated mice compared
to wild-type animals [80]. Interestingly, CNTF expression
reduced the activity levels of mice expressing mutated
huntingtin compared to control animals. Thus, sustained
striatal expression of CNTF can be achieved with lentivi-
ruses [80]. By contrast intrastriatal lentiviral vector transfer
of GDNF, performed at 5 weeks of age, does not amelio-
rate neurological and behavioral impairments in the R6/2
transgenic mice model of Huntington’s disease [85].
Another hypothesis for the disease suggested that
dopamine, found in high concentrations in the striatum,
may play a role in striatal cell death by increasing the
toxicity of an N-terminal fragment of mutated huntingtin
(Htt-171-82Q) [86, 87]. Stimulation of the dopamine D2
receptor (DR2) with haloperidol protects striatal neurons
from dysfunction induced by mutated huntingtin [88].
Mutant huntingtin causes disruption of mitochondrial
function by inhibiting expression of PGC-1a, i.e., a tran-
scriptional co-activator that regulates several metabolic
processes, including mitochondrial biogenesis and respi-
ration, and lentiviral-mediated delivery of PGC-1a in the
striatum provides neuroprotection in the transgenic mice
models [89]. Mitochondrial complex III-mediated modu-
lation of huntingtin aggregates was observed in a neuronal
progenitor RN33B cell line transduced by lentivirus car-
rying mutant huntingtin [90]. Mitochondrial complex II
protein (mCII) levels are reduced in striatum of patients,
notably the 30-kDa iron-sulfur subunit and the 70-kDa
FAD subunit [86], indicating that this complex may be
important for dopamine-mediated striatal cell death. Len-
tiviral-mediated expression of Htt171-82Q preferentially
decreased the levels of these subunits in vitro and affected
the dehydrogenase activity of the complex [86]. Dopamine-
induced down-regulation of mCII levels can be blocked by
several dopamine D2 receptor antagonists [87]. Lentiviral-
mediated overexpression of mCII subunits abrogated the
effects of dopamine, both by high dopamine concentrations
alone and neuronal death induced by low dopamine con-
centrations together with Htt-171-82Q [87]. Thus, lentiviral
treatment enabled to explore a novel pathway that links
dopamine signaling and regulation of mCII activity, and
provides insights for a key role for oxidative energy in the
disease.
Parkinson’s
Parkinson’s disease is characterized by a progressive loss
of midbrain dopamine neurons and the presence of cyto-
plasmic inclusions called Lewy bodies. Several approaches
have been developed using lentiviral-mediated gene
transfer technologies [91–94]. Mutations in several genes
have been linked to familiar Parkinson’s, including
a-synuclein and parkin. Parkin is a protein that functions
within a multiprotein E3 ubiquitin ligase complex, cata-
lyzing the covalent attachment of ubiquitin moieties onto
substrate proteins and thus promoting degradation of spe-
cific substrates in cells. It is characterized by its ubiquitin-
like motive at the N-terminus, and two RING fingers
domains (RING I and RING II) and one ‘‘in-between RING
finger motives’’ at the C-terminus [95]. Parkin may protect
neurons against a-synuclein toxicity, proteasomal dys-
function and kainate-induced excitotoxicity and may play a
role in controlling neurotransmitter trafficking at the pre-
synaptic terminal and in calcium-dependent exocytosis.
The protein carries out its activity by polyubiquitinating
substrates through its lysine 48 residue for proteasome-
dependent degradation [96], but it can also promote a
proteasome-independent process by lysine 63-linked
ubiquitination, which is a signal for ribosomal function,
endocytosis of membrane proteins, protein sorting and
trafficking [97, 98]. The loss of parkin’s E3-ligase activity
leads to dopaminergic neuronal degeneration in early onset
autosomal recessive juvenile parkinsonism, suggesting a
key role of parkin for dopamine neuron survival. Thus its
overexpression may provide a novel strategy for neuro-
protection in the disease [99]. In a rat lentiviral model of
Parkinson’s, animals overexpressing parkin showed sig-
nificant reductions in a-synuclein-induced neuropathology,
including preservation of tyrosine hydroxylase-positive cell
bodies in the substantia nigra [100]. The parkin-mediated
neuroprotection was associated with an increase in hyper-
phosphorylated a-synuclein inclusions, suggesting a key
role for parkin in the genesis of Lewy bodies.
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As another approach, reactive oxygen species are con-
sidered to contribute to the pathogenesis of the disease.
Therefore, antioxidative gene therapy strategies may be
relevant as a therapeutical approach. Indeed, lentivirus-
mediated expression of the antioxidant enzyme glutathione
peroxidase provides small but significant neuroprotection
against drug-induced toxicity [101], and could be suitable
as a potential neuroprotective approach. In addition, an
abnormal accumulation of cytosolic dopamine resulting in
reactive oxygen species and dopamine–quinone products
plays an important role in the selective degeneration of
substantia nigra pars compacta dopaminergic neurons in
Parkinson’s disease. The neuronal-specific vesicular
monoamine transporter (VMAT2), responsible for uptake
of dopamine into vesicles, has been shown to play a central
role both in intracellular dopamine homeostasis and
sequestration of dopaminergic neurotoxins. Lentivirus-
mediated transfection of VMAT2 increases intracellular
dopamine content, augments potassium-induced dopamine
release and attenuates cell death, and enhances vesicular
dopamine storage [102]. The opposite was seen after
downregulation of VMAT2 using virally delivered shR-
NAs [102].
Furthermore, growth factors such as glial cell line-
derived neurotrophic factor (GDNF) have been shown to
prevent neurodegeneration and promote regeneration in
many animal models of Parkinson’s disease [103]. MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neuro-
toxin used to study the disease in animal models (mainly
monkeys) that causes permanent symptoms of Parkinson’s
disease by killing certain neurons in the substantia nigra of
the brain. MPTP is metabolized into the toxic cation
1-methyl-4-phenylpyridinium (MPP?) by the enzyme
MAO-B of glial cells, which primarily kills dopamine-
producing neurons in a part of the brain called the pars
compacta of the substantia nigra. Infusion of recombinant
human GDNF into the rat striatum markedly protected
dopamine neurons against MPP?-induced toxicity [104],
and thus GDNF is a good candidate agent for restoring
functional reinnervation and/or neuroprotection of dopa-
mine nigrostriatal system for the treatment of Parkinson’s
disease [94]. Recently, recombinant LVs were developed
and used for effective GDNF gene delivery [3, 92–94,
105]. In vivo gene delivery of LV-GDNF has been widely
investigated [106] and viral delivery of GDNF currently
represents one of the most promising neuroprotective
strategies for Parkinson’s Disease [100]. However, one of
the important unresolved issues for this strategy is the
threshold number of dopamine (DA) nigral neurons and/or
of striatal DA terminals necessary for optimal benefit from
GDNF therapy [94]. Intracerebral injection of LV-GDNF
into 6-hydroxy-dopamine (6-OHDA) lesioned rats [107–
110] and MPTP-treated monkeys [105, 111] resulted in
persistent protection of the nigrostriatal DA pathway and
recovery of motor function [93, 108, 109, 112, 113],
thereby strongly supporting their application in the clinic.
Intrastriatal neurotrophic effects of long-term GDNF
delivery using a lentiviral vector restored complete stria-
tal dopamine innervation in the previously denervated
area, and this was associated with significant behavioral
improvements in a model of early Parkinson’s disease [94].
Apomorphine-induced rotation was significantly decreased
in the LV-GDNF-injected group compared to control ani-
mals [3] and GDNF efficiently protected 69.5% of the
tyrosine hydroxylase-positive cells in the substantia nigra
against 6-hydroxydopamine-induced toxicity. LV-GDNF
treatment induced substantial sprouting from surviving DA
axons, in agreement with previous work [75, 105, 114].
Interestingly, aberrant sprouting was not observed, and
consequently, negative functional effects such as those
presented by animals with extensive sprouting in or adja-
cent to the substantia nigra [75, 109] were not observed.
However, a rat model has been used which develops a
progressive and selective loss of dopamine neurons asso-
ciated with the appearance of a-synuclein containing
inclusions, thus recapitulating the major hallmarks of
Parkinson’s disease. In this model, a lentiviral vector
coding for GDNF (lenti-GDNF) was tested for its ability to
prevent nigral dopaminergic degeneration associated with
the lentiviral-mediated expression of the A30P mutant
human a-synuclein (lenti-A30P). When injected in the
substantia nigra 2 weeks before nigral administration of
lenti-A30P, it induced robust expression of GDNF but did
not prevent the a-synuclein-induced dopaminergic neuro-
degeneration, indicating that sustained GDNF treatment
cannot modulate the cellular toxicity related to abnormal
protein accumulation [115]. Recently, however, in an
encouraging primate study, Kordower et al. [105] injected
LV-GDNF into striatum and substantia nigra 1 week after
an intracarotid injection of the MPTP toxin, selectively
damaging the dopamine system [103]. In 3 months, motor
deficits were reversed and loss of TH-positive neurons in
the nigra had been prevented, while TH-positive projec-
tions to the striatum were preserved. Thus, if GDNF is
delivered at the lesion site before neurodegeneration pro-
gresses too far, LV-mediated GDNF treatments displays
impressive efficiency and induces functional reinnervation,
in both rodents and monkeys, which may provide a basis
for new clinical trials [103].
Finally, as an alternative, human neural progenitor cells
hold great potential as an ex vivo system for delivery of
therapeutic proteins to the central nervous system. When
cultured as aggregates (neurospheres), they are capable of
significant in vitro expansion. Methods have been devel-
oped for lentiviral vector-mediated gene delivery into
human neural progenitor cells that maintain their
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differentiation and proliferative properties, and result in
long-term, stable expression, and these cells have been
successfully transplanted into a rodent model of Parkin-
son’s disease, inducing stable neuroprotection [116]. Using
a similar approach, Ebert et al. [117] produced human
neural progenitor cells releasing either GDNF or Insulin-
like growth factor 1 (IGF-1) and transplanted them into a
rat model of PD. IGF-1, like GDNF, is also known to have
neuroprotective effects in a number of disease models but
has not been extensively studied in models of PD. Pro-
genitor cells secreting either GDNF or IGF-1 significantly
reduced amphetamine-induced rotational asymmetry and
dopamine neuron loss [117]. Interestingly, GDNF, but not
IGF-1, was able to protect or regenerate TH-positive fibers
in the striatum, whereas in contrast, IGF-1, but not GDNF,
significantly increased the overall survival of progenitor
cells both in vitro and following transplantation [117]. In
areas of GDNF delivery increased TH- and VMAT2-
positive fibers (vesicular monoamine transporter 2) was
also observed, which may regulate the sensitivity of rat
dopaminergic neurons to disturbed cytosolic dopamine
levels.
Together these studies show that lentiviral vectors
constitute a powerful gene delivery system for the
screening of therapeutic molecules in mouse models of
Parkinson’s disease [3, 91, 118]. Due to their impressive
efficiency, time may now be ripe to explore these vector
systems as tools for neuroprotective treatments in patients
with Parkinson’s disease [113].
Alzheimer’s Disease
Alzheimer’s disease is associated with the accumulation of
insoluble plaques of amyloid protein (APP) in the central
nervous system, as well as intracellular microfibrillar tan-
gles, along with loss of cholinergic neurons projecting from
the basal forebrain to the hippocampus and amygdala.
Plaque deposition is a result of overproduction of amyloid-
b protein (Abeta) through the activity of c-secretase, of
which the presenilins are thought to be a component. Early
onset familial Alzheimer’s, for example, is associated with
mutations in presenilin genes PS1 and PS2 which lead to
over secretion of Abeta. RNAi knockdown of PSN results
in a blockage of c-secretase activity [119]. Also siRNAs
targeting the b-secretase, BACE1, were shown to reduce
APP production in mouse cortical neurons, offering a
potential therapeutic approach for AD [120]. Lentiviruses
targeting selective genes involved in the disease have been
very powerful in better clarifying their functions in the
disorder.
Amyloid-b protein (Abeta) is derived from APP by
sequential cleavages of b- and c-secretases. The molecules
responsible for these proteolytic activities have been
identified [121]. The presenilin 1 and 2 are c-secretase, and
the identity of b-secretase has been shown to be the novel
transmembrane aspartic protease, b-site APP cleaving
enzyme 1 (BACE1; also called Asp2 and memapsin 2).
BACE2, a protease homologous to BACE1, was also
identified, and together the two enzymes define a new
family of transmembrane aspartic proteases [121]. b-Site
APP cleaving enzyme 1 (BACE1) is the major b-secretase
in vivo. Burton [122] designed a number of siRNA target
sequences and cloned them into lentivirus vectors and
showed that RNA inhibition of b-secretase reverts Alz-
heimer’s disease in mice [122]. Sierant et al. [123]
designed lentivirus vector-encoded siRNAs for efficient
knockdown of overexpressed and endogenous BACE1 in a
rat brain and also the allele-specific siRNAs to silence the
mutant presenilin 1 (L392V PS-1), the main component of
c-secretase. This results in strongly reducing the level of
b-amyloid accumulation in the brain. These tools could be
beneficial for potential therapeutic approach for treatment
of the disease [123]. In another study, Singer et al. [124]
targeted BACE1 with siRNAs. Lowering BACE1 levels
using these lentiviral vectors expressing siRNAs targeting
BACE1 reduced amyloid production and the neurodegen-
erative and behavioral deficits in APP transgenic mice, an
approach that could have potential therapeutic value for
treatment of the disease [124]. b-Site APP cleaving enzyme
2 (BACE2) is the homologue of BACE1 and cleaves APP
at a novel theta site downstream of the a site, abolishing
Abeta production [125]. Overexpression of BACE2 by
lentivirus markedly reduced Abeta production in primary
neurons derived from Swedish mutant APP transgenic
mice. This suggests that therapeutic interventions that
potentiate BACE2 may prevent AD pathogenesis [125].
Besides, El-Amouri et al. [126] targeted neprilysin (NEP),
the dominant Abeta peptide-degrading enzyme in the brain.
NEP becomes inactivated and down-regulated during both
the early stages of AD and aging. Lentivirus-mediated
overexpression of human NEP for 4 months in young APP/
DPS1 double-transgenic mice resulted in reduction in Ab-
eta peptide levels, attenuation of amyloid load, oxidative
stress, and inflammation, and improved spatial orientation.
The overall reduction in amyloidosis and associated path-
ogenetic changes in the brain resulted in decreased memory
impairment by approximately 50%. Thus, restoring NEP
levels in the brain at the early stages of AD is an effective
strategy to prevent or attenuate disease progression. The
cysteine protease cathepsin B (CatB) is also associated
with amyloid plaques in AD brains and reduces levels of
Abeta peptides, especially the aggregation-prone species.
Lentivirus-mediated expression of CatB in aged hAPP
mice reduced preexisting amyloid deposits [127], even
thioflavin S-positive plaques. Under cell-free conditions,
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CatB effectively cleaved Abeta1-42, generating C-termi-
nally truncated Abeta peptides that are less amyloidogenic
and increasing CatB activity could counteract the neuro-
pathology of this disease [127, 128].
Apolipoprotein E (apoE) alleles are important genetic
risk factors for Alzheimer’s disease (AD), which influence
brain amyloid-b peptide (Abeta) and amyloid burden. Direct
intracerebral administration of lentiviral vectors expressing
the three common human apoE isoforms differentially alters
hippocampal Abeta and amyloid burden in mouse model of
AD [129]. Expression of apoE4 in the absence of mouse
apoE increases hippocampal Abeta [1–42] levels and amy-
loid burden. By contrast, expression of apoE2, even in the
presence of mouse apoE, markedly reduces hippocampal
Abeta burden. Thus gene delivery of apoE2 may reduce the
development of neuritic plaques [129].
Recently, Kim showed that SIRT1, a human homolog of
SIR2 (a gene which promotes longevity in a variety of
organisms), is upregulated in mouse models for Alzhei-
mer’s disease [130]. Injection of SIRT1-expressing lenti-
virus in the hippocampus of the inducible p25 transgenic
mice (a model of AD) conferred significant protection
against neurodegeneration, reduced neurodegeneration in
the hippocampus, prevented learning impairment, and
decreased the acetylation of the known SIRT1 substrates
PGC-1a and p53 [130]. Neurodegeneration induced by
pathogenic proteins depends on contributions from sur-
rounding glia. In Alzheimer’s disease, NF-jB signaling in
microglia is critically involved in neuronal death induced
by Abeta peptides. Stimulation of microglia with Abeta
increases acetylation of RelA/p65, which regulates the NF-
jB pathway. Overexpression of SIRT1 deacetylase and the
addition of the SIRT1 agonist resveratrol markedly reduce
NF-jB signaling stimulated by Abeta and has strong neu-
roprotective effects, which support a glial loop hypothesis
by demonstrating a critical role for microglial NF-jB sig-
naling in Abeta-dependent neurodegeneration [131].
Microglia, the immune cells of the brain, are activated in
the brain of Alzheimer’s disease patients, and express the
innate immune receptor toll-like receptor 2 (TLR2).
Richard et al. [132] generated triple transgenic mice defi-
cient in TLR2 and harboring a mutant human presenelin 1
and a chimeric mouse/human amyloid precursor protein
(APP). TLR2 deficiency accelerated spatial and contextual
memory impairments, which correlated with increased
levels of Abeta [1–42] and transforming growth factor b1
in the brain. Expression levels of N-Methyl-D-Aspartate
(NMDA) receptors 1 and 2A were also lower in the hip-
pocampus of APP-TLR2(-/-) mice. Gene therapy in cells
of the bone marrow using lentivirus expressing TLR2
rescued the cognitive impairment of APP-TLR2(-/-)
mice and restored the memory consolidation process dis-
rupted by TLR2 deficiency in APP mice [132].
Drug Addiction
Drug addiction is a major public health issue. It is typically
a multi-genetic brain disorder, implying combined changes
of expression of several hundred genes. Addictive drugs
(cocaine and amphetamines), depressants (ethanol), and
opiate narcotics (heroin and morphine) are powerful rein-
forcers and produce their rewarding effects of euphoria
or pleasure through an interaction with the mesolimbic
dopamine system [133]. The dopamine D3 receptor (D3R)
is an important pharmacotherapeutic target for its potential
role in psychiatric disorders and drug dependence. Lenti-
virus-mediated manipulations of D3R levels, using local
injection in the Accumbens of combinations of either D3R-
expressing and/or siRNAs-expressing lentiviruses induced
strong behavioral changes in the locomotor stimulant
effects of cocaine [134]. Suppression of D3R expression
increased locomotor stimulant effects, whereas its over-
expression with lentivirus-expressing D3R drastically
reduced them. The latter effects could be reversed when
animals were fed doxycycline, which prevented ectopic
overexpression of D3R in the Accumbens [134]. In the
mesolimbic dopaminergic pathway, dopamine is removed
by its transporter DAT. Lentivirus-mediated overexpres-
sion of DAT in the nucleus Accumbens induced a 35%
decrease in locomotor activity, which could be abolished
when the same animal was fed doxycycline, whereas local
inhibition of DAT in the this brain area, using lentiviruses
expressing siRNAs targeted against DAT, resulted in sig-
nificant hyperlocomotion activity (72% increase over
controls) [135]. a-Synuclein binds to the dopamine and
serotonin transporters (DAT and SERT), affecting their
activities and their recruitment to the plasma membrane, an
effect that can be modulated by c-synuclein expression
[136, 137]. Local manipulation of either a- or c-synuclein
expression, by means of lentiviruses expressing either
genes or siRNAs targeted against them, strongly affected
cocaine-induced behavioral effects and c-synuclein modu-
lates cocaine-induced reinforcing and incentive effects
[138, 139].
Strong molecular adaptations and plasticity within this
mesolimboc dopaminergic pathway upon administration of
drugs underlie a complex rewiring of neural circuitry that
results in the behaviors associated with addiction [133,
140]. Little is known about the specific targets involved in
this neuroadaptation process but it has been suggested that
cocaine and other drugs of abuse may alter the morphology
of neuronal dendrites and spines, the primary site of
excitatory synapses in the brain, by means of inducing
expression changes of surface molecules [133, 141].
Complex changes in expression of a number of surface
axon guidance molecules have been observed upon cocaine
administration, which may underlie important neuroplastic
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changes in the reward- and memory-related brain centers
after drug action [142]. Local expression changes of these
cues may mediate plasticity and cytoskeleton rearrange-
ment through mechanisms similar to synaptic targeting
during development. In addition, strong induction of a
surface tetraspanin protein involved in cell adhesion,
CD81, has been described [143–145]. Tetraspanins are
scaffold proteins that integrate receptor signaling and form
complexes with integrins, to mediate axon growth induced
by numerous extracellular matrix proteins. Using a regu-
latable lentivirus bearing the rat CD81 gene under the
control of a tetracycline-inducible system, Bahi et al. [146]
showed that local overexpression of CD81 in this pathway,
by means of doxycycline-regulatable lentiviral-mediated
gene transfer into the nucleus Accumbens, induced a four-
to fivefold increase in locomotor activity, which can be
reversed to normal in the same animal fed doxycycline
[144, 146]. Furthermore several lentiviruses expressing
siRNA targeted against CD81 have been designed and
CD81 gene silencing was assessed in vivo upon local,
stereotaxic injection into the ventral tegmental area (VTA)
or the Nucleus Accumbens (NAcc) [147]. Expression of
siRNA targeted against CD81 decreased CD81-mediated
locomotor activity almost back to basal levels, and could
be regulated by very local and specific gene knockdown, a
clear indication that drug-mediated behavioral activity is
strongly modulated by this tetraspanin [147].
A similar approach was used to assess the role of other
genes in drug addiction. Among these the plasminogen
system is particularly intriguing. Extracellular proteolytic
processes play a key function in regulating synaptic struc-
ture and function, and CNS plasticity. Among these, plas-
minogen activators are important mediators of extracellular
metabolism, involved in remodeling events during devel-
opment and regeneration in the nervous system. The gen-
eration of plasmin from its inactive precursor plasminogen is
mediated by serine enzymes known as tissue-type plas-
minogen activator (tPA) and urokinase (uPA), and contrib-
utes to the turnover of the extracellular matrix in the CNS.
Urokinase-type plasminogen activator (uPA) exerts a vari-
ety of functions during development, and is involved in
learning and memory. Several tetraspanins drastically affect
plasmin activity and prevent uPA binding to its receptor
uPAR by promoting stable association of uPAR with spe-
cific integrins (e.g., a5b1), redistributing uPAR to focal
adhesion. A screening for genes induced after drug treatment
showed that urokinase plasminogen-type activator (uPA)
was strongly regulated by cocaine in several paradigms of
drug administration [148]. Lentiviral-mediated injection of
a doxycycline-regulated uPA expression cassette, (or of its
mutated form) into specific rat brain areas (Hippocampus,
nucleus Accumbens and Ventral Tegmental Area) showed a
dramatic, doxycycline-dependent, 10- to 12.3-fold increase
in locomotor activity after cocaine administration [148].
Behavioral effects were completely abolished when uPA
expression was turned off with doxycycline or when the
active site of the protease was point-mutated and used as a
dominant negative [148, 149]. Lentiviral-mediated overex-
pression of uPA in the VTA induces doxycycline-dependent
expression of its receptor, uPAR, but not its inhibitor,
plasminogen activator inhibitor-1 (PAI-1) [149]. Local
injection of uPA-specific siRNAs expressing lentiviruses
into the ventral tegmental area suppressed cocaine-induced
behavioral changes associated with uPA expression [149,
150] Lentivirus-mediated overexpression of uPA in the
Accumbens shell significantly augments cocaine-induced
place preference, whereas its inhibition abolished the
acquisition but not the expression of cocaine-induced place
preference [149, 150]. Furthermore, while this overexpres-
sion did not affect the ability of preference to be extin-
guished, reinstatement with a low dose of cocaine produced
significantly greater preference to the cocaine-associated
context. Thus once place preference had been established,
and the preference extinguished, reinstatement induced by a
priming dose of cocaine is facilitated by uPA. Furthermore,
lentivirus-mediated overexpression of uPA induces
cocaine-, but not amphetamine-mediated behavioral chan-
ges, whereas, in contrast, tPA-overexpressing animals
displayed greater place preference when administered
amphetamine or morphine compared to uPA-overexpressing
animals [149–151]. The behavioral effects are suppressed
when tPA has been silenced using specific siRNAs-
expressing lentiviruses. Suppression of endogenous tPA
expression in animals treated with siRNA-expressing len-
tiviruses also fully suppresses place preference and these
animals appear to avoid the drug-associated box. In addition,
lentivirus-mediated tPA overexpression delays extinction,
but priming with low doses of amphetamine (not cocaine)
reinstates place preference even after full extinction. Thus
tPA plays an important role in acquisition of amphetamine-
induced conditioned place preference but its role in place
preference-expression does not seem important [151, 152].
Together these data indicate that tPA and uPA may induce
distinct behaviors, which may be interpreted according to
their differential pattern of activation and downstream tar-
gets. Thus, modulation of the plasminogen system in the
brain might be a potential target against drugs of abuse [153].
Furthermore, the neurotrophin BDNF (brain-derived
neurotrophic factor) is also involved in cocaine reward and
relapse. BDNF is involved in the survival and function of
midbrain dopamine neurons, mediated by its TrkB recep-
tor. BDNF and TrkB transcripts are widely expressed in the
mesolimbic pathway, including the Nucleus Accumbens
(NAc) and the Ventral Tegmentum Area (VTA). Lentivi-
ruses expressing either BDNF or TrkB enhance drug-
induced locomotor activity and induce sensitization in rats
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[135]. Upon local treatment, animals display enhanced
cocaine-induced place preference, delayed place prefer-
ence-extinction and increased reinstatement. Lentiviral-
mediated expression of TrkT1 (truncated form of TrkB,
acting as a dominant negative) inhibits these behavioral
changes. This inhibition is also observed when rats are fed
doxycycline (blocking local, lentivirus-mediated gene
expression) or when injected with siRNAs-expressing
lentiviruses against TrkB [135]. This approach enabled to
show that BDNF and TrkB-induced place preference takes
place during the learning period (conditioning) whereas
extinction leads to the loss of place preference. Extinction
is delayed when rats are injected BDNF- or TrkB-
expressing lentiviruses, whereas priming injections of
cocaine reinstates it.
Attention-Deficit Hyperactivity Disorder (ADHD)
Attention-Deficit Hyperactivity Disorder (ADHD) is a
neurobehavioral developmental disorder, characterized by
a persistent pattern of impulsiveness and inattention, with
or without a component of hyperactivity [154]. According
to the dominant model, ADHD is viewed as an executive
dysfunction [155–157], but alternative accounts present
ADHD as a motivational dysfunction [158], arising from
altered reward processes within fronto-striatal circuits
[159, 160]. Comorbidity to ADHD and other impulse-
control disorders is pathological gambling as well as
common, especially compulsive buying and compulsive
sexual behavior [161]. The disorder is highly heritable and
arises from a combination of various genes, many of which
affect dopamine transporters. Psycho-genetic studies have
revealed that, among several genes involved in DAergic
neuro-transmission within the reward system, one of the
most significant being the dopamine transporter (DAT)
[162]. Besides, candidate genes include the dopamine
receptor D4 [163], dopamine b-hydroxylase [164], mono-
amine oxidase A, catecholamine-methyl transferase, seroto-
nin transporter promoter, and serotonine receptors 5-HT2A
and 5-HT1B [165, 166].
Adriani et al. [167] tested the role of striatal dopamine
function in ADHD using lentiviruses driving the expression
of DAT or siRNAs targeted against DAT mRNA in the
Nucleus Accumbens of rats. These tools enabled us to
evaluate behavioral changes, associated with very local
DAT over-expression or suppression [167]. Accumbal DAT
suppression was expected to enhance tonic DA transmis-
sion, compared to controls, whereas its over-expression
would drastically reduce synaptic DA levels. To probe the
resulting behavioral phenotype, animals were tested for
several motivational endpoints such as seeking for novelty,
intolerance to delay, and temptation to gamble [168, 169].
Whereas all knockout mice models have the major
disadvantage that the gene is absent all over the CNS,
lentivirus-mediated DAT manipulation is very local and
only initiated in mature animals. Rats were followed both
for socio-emotional profiles and for risk-seeking propen-
sity. Elevated anxiety and affiliation toward a stranger
emerged upon silencing DAT in the nucleus Accumbens, in
rats stereotaxically injected with LV-expressing shRNA
targeted to DAT. Interestingly, using a doxycycline-regu-
latable lentivirus overexpressing DAT showed that levels
of playful social interaction were markedly reduced,
compared to controls. These rats displayed a marked
‘‘gambling’’ profile (i.e., preference for a large/uncertain
over a small/sure reward), which disappeared upon doxy-
cycline-induced switch-off on DAT enhancer, and consis-
tently reappeared with doxycycline removal [167]. This
powerful tool allowed to reproduce an integrated profile in
a regulatable way and shows that lentiviral vectors are
suitable tools for animal models to reproduce psychiatri-
cally relevant symptoms.
Other Disorders
In vivo gene delivery by means of lentiviral vector-medi-
ated gene transfer has been used for assessing gene function
of many other pathologies. In many cases lentiviral-medi-
ated in vivo delivery of shRNAs targeting a major candidate
has also been attempted.
Rett Syndrome
The methyl-CpG-binding protein-2 gene (Mecp2) is the
causal gene of the neurodevelopmental disorder, Rett
Syndrome. A rat model with a downregulated Mecp2 was
established using a recombinant lentiviral vector express-
ing small hairpin RNA of the rat Mecp2 gene [170]. Four
recombinant vectors were constructed by inserting
sequences of small hairpin RNA targeting the rat Mecp2
gene. Rats were given intraventricular injections. Mecp2
mRNA was lower in the hippocampus and cerebral cortex
relative to control groups. Although no typical Rett-like
symptoms were observed, the neonatal rats injected with
recombinant lentivirus displayed some transient neurobe-
havioral abnormalities during early development [170].
BDNF mRNA expression decreased in the hippocampus,
supporting the hypothesis that BDNF may be a target gene
of MeCP2 in the CNS [170]. Furthermore, by means of a
lentivirus expressing Cre recombinase, Nelson et al. [171]
showed that loss of MeCP2 function after neurodevelop-
ment and synaptogenesis was sufficient to mimic the
decrease in the frequency of spontaneous excitatory syn-
aptic transmission seen in constitutive MeCP2 KO neurons
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[171]. Taken together, these results suggest a role for
MeCP2 in control of excitatory presynaptic function
through regulation of gene expression.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a fatal neurode-
generative disease resulting in the selective death of motor
neurons in the brain and spinal cord. Mutations in Cu/Zn
superoxide dismutase (encoded by SOD1) is one of the
causes of familial amyotrophic lateral sclerosis, which
leads to progressive death of motoneurons through a gain-
of-function mechanism. RNA interference (RNAi) medi-
ated by lentiviral vectors allows for long-term reduction in
gene expression and represents an attractive therapeutic
approach for genetic diseases characterized by acquired
toxic properties [172]. Lentiviral vectors mediating expres-
sion of RNAi molecules specifically targeting the human
SOD1 gene (SOD1) have been designed and injected into
various muscle groups of mice engineered to overexpress
a mutated form of human SOD1 (SOD1G93A), which
resulted in an efficient and specific reduction of SOD1
expression and improved survival of vulnerable motor
neurons in the brainstem and spinal cord [172]. Further-
more, in SOD1G93A transgenic mice (a model for familial
ALS) intraspinal injection of a lentiviral vector that pro-
duces RNAi-mediated silencing of SOD1 substantially
retards both the onset and the progression rate of the
disease [172, 173].
Scrapie
Prion diseases are fatal neurodegenerative diseases char-
acterized by the accumulation of PrPSc, the infectious and
protease-resistant form of the cellular prion protein (PrPC).
Pfeiffer et al. [174] generated lentivectors expressing
PrPC-specific shRNAs that efficiently silenced expression
of the prion protein gene (Prnp) in primary neuronal cells.
Treatment of scrapie-infected neuronal cells with these
lentivectors resulted in an efficient and stable suppression
of PrPSc accumulation. After intracranial injection, len-
tiviral shRNA reduced PrPC expression in transgenic mice
carrying multiple copies of Prnp [174].
Glioma
Glioma cells are characterized by their invasiveness and
resistance against conventional therapeutics. Telomerase
activity has been suggested to be an important target for
glioma treatment. Zhao et al. [175] assessed the anticancer
effects of lentiviral vector-mediated siRNA knockdown of
the human telomerase reverse transcriptase (hTERT) in
U87MG human glioblastoma cells and in vivo. Injection of
lentiviral vectors significantly inhibited the growth of
preestablished macroscopic xenograft tumors. The in vivo
glioma growth inhibition effect coincided with no detect-
able telomere length changes [2, 175]. Thus, efficient
knockdown of hTERT can inhibit glioma cell proliferation
and migration prior to its effect on telomere length.
Spinal Cord Injury
Injuries to the adult mammalian spinal cord often lead to
severe damage to both ascending (sensory) pathways and
descending (motor) nerve pathways without the perspective
of complete functional recovery. Neurotrophins have
emerged as promising molecules to augment neuroprotec-
tion and neuronal regeneration. Recently, lentiviral vector-
mediated gene transfer of neurotrophins has been tested
successfully in order to promote regeneration of the injured
spinal cord [176]. Furthermore, a conditioning lesion to
peripheral axons of primary sensory neurons accelerates
regeneration of their central axons in vivo or neurite out-
growth. Neuropoietic cytokines are also involved in this in
regenerative conditioning [177]. Delivery through a lenti-
virus vector of ciliary neurotrophic factor to the appropriate
dorsal root ganglion in rats effectively mimics the condi-
tioning effect of peripheral nerve injury on the regeneration
of dorsal spinal nerve root axons [177].
Other Uses
Finally, lentiviral-mediated gene transfer has further great
potential and applications. For example, human neural
progenitor cells hold great potential as an ex vivo system for
delivery of therapeutic proteins to the central nervous sys-
tem, because, as aggregates (neurospheres), they are
capable of significant expansion. Capowski et al. [116]
developed lentiviral-mediated genetic modification of
human neural progenitor cells for ex vivo gene therapy,
which maintains the differentiation and proliferative prop-
erties of neurosphere cultures while minimizing the amount
of viral vector used and controlling the number of insertion
sites per population. This method results in long-term stable
expression even after differentiation of progenitor cells to
neurons and astrocytes and may have great therapeutic
potential. On another approach, Dittgen et al. [178] estab-
lished a method for genetic manipulation and subsequent
phenotypic analysis of individual cortical neurons in vivo.
Lentiviral vectors were prepared for neuron-specific gene
delivery from either calcium-calmodulin-dependent protein
kinase II promoter or from Synapsin I promoter, optionally
in combination with gene knockdown by means of U6
promoter-driven expression of short-interfering RNAs
[178]. These tools may be ideally suited for analysis of gene
functions in individual neurons in the intact brain.
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Similarly, Kameda developed lentiviral vectors for target-
ing green fluorescent protein specifically to dendritic
membrane in central neurons [179]. Using a lentivirus with
a neuron-specific promoter, GFP with a palmitoylation
(palGFP) or myristoylation/palmitoylation site (myrGFP)
was expressed in rat brain to target dendritic membranes
efficiently. myrGFP tagged with the C-terminal cytoplasmic
domain of low density lipoprotein receptor proved to be an
excellent synthetic protein for dendritic visualization, and
may be a useful tool for the morphological analysis of
neuronal circuits [179]. In an even more specific approach,
Santamaria developed lentiviral vector that produces
shRNA targeting choline acetyl-transferase (ChAT)
mRNAs and used this tool to transduce cholinergic neurons
in vivo [180], resulting in reduced ChAT expression
strongly and specifically in the cholinergic neurons of the
medial septum in adult rats, without affecting the expres-
sion of the vesicular acetylcholine transporter. This lentiv-
iral vector is thus a powerful tool for specific inactivation of
cholinergic neurotransmission and can, therefore, be used to
study the role of cholinergic nuclei in the brain.
Conclusions
RNA interference has now developed into a very powerful
approach toward therapy for neural disorders [181], and
many gene delivery strategies for RNAi knockdown of
neuronal genes have been tested. In this review I have
shown the applications of lentivirus-mediated gene transfer
in the investigation of a large variety of brain disorders. As a
matter of fact, lentiviral vectors are increasingly used for
gene delivery to neurons and in experimental models of
brain disorders. Their use in gene delivery has received
greatest attention and the use of neuron-specific promoters,
where introduced, enables cell-specific gene transfer in a
complex system such as the brain. The development of self-
inactivating lentiviruses enables also to very locally
manipulate the expression of a specific gene, in a very
specific and limited neuronal pathway within the brain. In
addition, the development of lentiviral systems has facili-
tated the exogenous manipulation of RNAi in hard to
transfect, postmitotic cells such as neurons. Lentiviral
vectors with their high tropism for neurons offer one of the
most attractive options for delivering shRNAs to the CNS,
as well as to cultured neurons and neuronal cell lines in
vitro. This approach has been successfully used to func-
tionally silence genes in primary mammalian cells, stem
cells and more importantly in transgenic mice, resulting in
persistent knockdown of gene expression. The use of len-
tiviruses for stable gene silencing in brain will soon prove a
powerful aid to probe gene function in vivo and for gene
therapy of diseases of the central nervous system.
Lentiviral-mediated RNAi experiments in cultured mam-
malian neurons can be designed to address a wide variety of
biological questions or to test potential therapeutic hairpins
before moving to treatment trials in vivo. Indeed, potent
silencing of gene expression in vitro and in vivo by len-
tiviral vector-based RNAi provide the tools for developing
effective gene silencing therapeutics for many major brain
disorders [182]. Experimental gene therapy approaches
under development using this technology are well advanced
today, particularly for motor disorders such as Parkinson’s
disease and related synucleinopathies, or Huntington’s
disease, dystonia or muscular dystrophy, as I have shown in
this review. Besides lentivirus gene transfer has been an
invaluable tool recently for evaluation of gene function in
highly complex behavioral disorders such as drug addiction
and attention-deficit hyperactivity disorder or in learning
and cognition. Many studies also include lentiviral-medi-
ated delivery of neurotrophic factor genes, anti-apoptotic
genes, and genes that modulate neurotransmission. Clearly
this technology will greatly help at a deeper understanding
of these complex disorders in future studies.
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